SOST and plasma cell myeloma: As a start to this endeavor, Delgado-Calle et al. recently reported that use of genetic deletion of sclerostin, a potent Wnt/beta-catenin antagonist, prevents the loss of bone in a mouse model of multiple-myeloma-induced bone disease.